Neuroblastoma: the challenge and frustration.
Neuroblastoma occurs in 500 children yearly in the United States. Recent findings in tumor biology and the evaluation of biochemical markers have been helpful in predicting outcome, but clinicians have not been able to exploit these findings to develop successful therapy. Staging is important, but it will be necessary to standardize staging at various centers to compare results of therapy. The role for autologous bone marrow transplantation in the management of neuroblastoma remains to be determined, and search for effective therapy continues. This disease has challenged cell biologists, it has served as a basis for intense scientific inquiry, and it has defied the therapeutic attempts of pediatric oncologists. It is hoped that current enquiry will inspire newer therapies and fulfill the goal of offering all children with this tumor an opportunity to be cured.